THE CORONAVIRUS & AURA AIR 
​​EFFICACY RESULTS PUBLISHED

We believe that Aura Air is the first Filtration/Purification/Monitoring system in the world to have undergone extensive efficacy tests, specifically related to its ability to reduce the levels of COVID-19 Coronavirus.  

Aura Air uses a combination of a patented Copper impregnated HEPA Filter, the patented Sterionizer and UV-C light.  Each of these technologies were tested on its effect on the Coronavirus.

After these (see link to the full white paper report above) excellent results, more detailed  Clinical Trials are taking placing in the special laboratory set up at Sheba Medical Centre* that diagnoses and accurately measures the levels of Coronavirus, using the latest, state of the art RNA measurement equipment – each unit costing nearly £100,000.

* Sheba Medical Center was ranked earlier this year by Newsweek as one of the Top 10 Hospitals in the World.

COPPER + HEPA = 99.97% REDUCTION ALONE!

 

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Summary of clinical trial

AURA AIR’S UNIQUE FILTRATION & DISINFECTION SYSTEM DEPLOYED AT SHEBA MEDICAL CENTRE TO HELP TO REDUCE COVID-19 INFECTION

 
 
Israel’s Sheba Medical Center, which has treated more than 300 COVID-19 patients since March 2020, is piloting the use of the unique air filtration, disinfection and monitoring system from Aura Air, spanning almost the entire duration of the COVID-19 Pandemic. The compact Aura Air system has now also been tested in staff rooms, operating rooms of patients diagnosed with the virus and rooms of at-risk patients.
 
Two Patented technologies go beyond traditional UV-C light to kill viruses and bacteria

 In previous lab experiments, the unique Aura Air system demonstrated an average of 99 percent effectiveness against influenza viruses H1N1 and H5N1, heavily contributed to by its unique Copper-impregnated HEPA Filter and patented Sterionizer technology.
​
“We started this pilot in order to help the ward in reducing potential infections.  Now, we are focused on purifying and sterilising the air of resistant viruses, including coronavirus (Covid-19),” Aviad Schneiderman, Aura Air’s CEO, and founding partner said in a statement. “In light of our impressive results on the anti-bacterial front, Aura Air is in the final stages of approval for funding by the European Union, who set a goal to find solutions for closed-space infections, with a special emphasis on the Coronavirus.”

“The etiologic agent used in these tests is an infectious bronchitis virus (IBV), from the coronavirus family. It is an enveloped, positive-sense, single-stranded RNA virus. The comparison of genome structures of SARS-CoV-2 and other coronaviruses shows that SARS-CoV-2 and IBV share the same genome structure and diameter.  We chose to use the IBV virus because it allows testing of a similar virus without endangering the medical staff at the hospital during the trial process” explains Olga Klebanov, Ph.D., The Surgical Oncology Laboratory, Department of General & Oncological Surgery – Surgery C, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan.

Sheeba test results

“In light of the impressive performance and results that Aura Air has achieved on the antibacterial level, we are in the final stages of receiving EU funding,” said Roy Friedberg, Vice President of Aura Air. “The goal is to target solutions for closed space infections in general, and the coronavirus in particular.”